Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Storz U. Rituximab: how approval history is reflected by a corresponding patent filing strategy. MAbs 6(4), 820–837 (2014).
  MedlineGoogle Scholar
• 2 Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 117(11), 2993–3001 (2011).
  Medline CASGoogle Scholar
• 3 Herter S, Herting F, Mundigl O et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12(10), 2031–2042 (2013).
  Medline CASGoogle Scholar
• 4 Leonard JP. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology Am. Soc. Hematol. Educ. Program doi:10.1182/asheducation-2005.1.335 335–339 (2005).
  MedlineGoogle Scholar
• 5 Menge T, Dubey D, Warnke C, Hartung HP, Stuve O. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Rev. Neurother. 16(10), 1131–1139 (2016).
  Medline CASGoogle Scholar
• 6 Gupta IV, Jewell RC. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann. NY Acad. Sci. 1263, 43–56 (2012).
  MedlineGoogle Scholar
• 7 Ibatici A, Pica GM, Nati S et al. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br. J. Haematol. 164(5), 710–716 (2014).
  Medline CASGoogle Scholar
• 8 Perez-Andres M, Paiva B, Nieto WG et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B. Clin. Cytom. 78(Suppl. 1), S47–S60 (2010).
  MedlineGoogle Scholar
• 9 Eisenberg RA, Jawad AF, Boyer J et al. Rituximab-treated patients have a poor response to influenza vaccination. J. Clin. Immunol. 33(2), 388–396 (2013).
  Medline CASGoogle Scholar
• 10 Marco H, Smith RM, Jones RB et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet. Disord. 15, 178 (2014).
  MedlineGoogle Scholar
• 11 Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin. Lymphoma Myeloma Leuk. 13(2), 106–111 (2013). •• Descriptive analysis of hypogammaglobulinemia in lymphoma patients treated with rituximab.
  Medline CASGoogle Scholar
• 12 De Angelis F, Tosti ME, Capria S et al. Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study. Leuk. Res. 39(12), 1382–1388 (2015).
  Medline CASGoogle Scholar
• 13 Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann. Oncol. 17(9), 1424–1427 (2006).
  Medline CASGoogle Scholar
• 14 De La Torre I, Leandro MJ, Edwards JC, Cambridge G. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin. Exp. Rheumatol. 30(4), 554–560 (2012).
  MedlineGoogle Scholar
• 15 Van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J. Rheumatol. 42(10), 1761–1766 (2015).
  Medline CASGoogle Scholar
• 16 Aguiar R, Araujo C, Martins-Coelho G, Isenberg D. Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res. (Hoboken) 69(2), 257–262 (2017).
  Medline CASGoogle Scholar
• 17 Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10(6), 548–551 (1998).
  Medline CASGoogle Scholar
• 18 Lim SH, Zhang Y, Wang Z et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant. 35(2), 207–208 (2005).
  Medline CASGoogle Scholar
• 19 Keystone E, Burmester GR, Furie R et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 59(6), 785–793 (2008).
  Medline CASGoogle Scholar
• 20 Kappos L, Li D, Calabresi PA et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a Phase II, randomised, placebo-controlled, multicentre trial. Lancet 378(9805), 1779–1787 (2011).
  Medline CASGoogle Scholar
• 21 Sorensen PS, Lisby S, Grove R et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a Phase II study. Neurology 82(7), 573–581 (2014).
  Medline CASGoogle Scholar
• 22 Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter Phase 2 study. Blood 112(4), 999–1004 (2008).
  Medline CASGoogle Scholar
• 23 Ghobrial IM, Fonseca R, Greipp PR et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 101(11), 2593–2598 (2004).
  Medline CASGoogle Scholar
• 24 Imamura T, Yoshihara T, Morimoto A, Ishida H, Sugimoto T, Imashuku S. Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma. Pediatr. Hematol. Oncol. 23(1), 19–24 (2006).
  Medline CASGoogle Scholar
• 25 Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359(3), 242–251 (2008). • Interventional study showing that combination of IVIG and Rituximab reduced alloantibody levels.
  Medline CASGoogle Scholar
• 26 Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr. Opin. Organ Transplant. 15(1), 8–10 (2010).
  MedlineGoogle Scholar
• 27 Clatworthy MR. Targeting B cells and antibody in transplantation. Am. J. Transplant. 11(7), 1359–1367 (2011).
  Medline CASGoogle Scholar
• 28 De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 64(3), 843–853 (2012).
  Medline CASGoogle Scholar
• 29 Terrier B, Saadoun D, Sene D et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum. 60(8), 2531–2540 (2009).
  Medline CASGoogle Scholar
• 30 Alberici F, Smith RM, Jones RB et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 54(7), 1153–1160 (2015).
  Medline CASGoogle Scholar
• 31 Venhoff N, Effelsberg NM, Salzer U et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE 7(5), e37626 (2012).
  Medline CASGoogle Scholar
• 32 Bomm L, Fracaroli TS, Sodre JL, Bressan A, Gripp AC. Off-label use of rituximab in dermatology: pemphigus treatment. An. Bras. Dermatol. 88(4), 676–678 (2013).
  MedlineGoogle Scholar
• 33 Tokunaga M, Fujii K, Saito K et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44(2), 176–182 (2005).
  Medline CASGoogle Scholar
• 34 Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8(3), R83 (2006).
  MedlineGoogle Scholar
• 35 Fervenza FC, Abraham RS, Erickson SB et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin. J. Am. Soc. Nephrol. 5(12), 2188–2198 (2010).
  Medline CASGoogle Scholar
• 36 Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC. Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin. Nephrol. 77(4), 290–295 (2012).
  Medline CASGoogle Scholar
• 37 Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am. J. Manag. Care 9(5), 393–400; quiz 401–392 (2003).
  MedlineGoogle Scholar
• 38 Cattaneo C, Spedini P, Casari S et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk. Lymphoma 47(6), 1013–1017 (2006).
  Medline CASGoogle Scholar
• 39 Khan DA. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. Ann. Allergy Asthma Immunol. 117(2), 115–120 (2016).
  Medline CASGoogle Scholar
• 40 Adeli MM, Eichner BH, Thornburg C, Williams L. Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. Pediatr. Hematol. Oncol. 26(8), 566–572 (2009).
  Medline CASGoogle Scholar
• 41 Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J. Allergy Clin. Immunol. Pract. 2(5), 594–600 (2014).
  MedlineGoogle Scholar
• 42 Levy R, Mahevas M, Galicier L et al. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun. Rev. 13(10), 1055–1063 (2014).
  Medline CASGoogle Scholar
• 43 Quartier P, Tournilhac O, Archimbaud C et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin. Infect. Dis. 36(3), e47–e49 (2003).
  MedlineGoogle Scholar
• 44 Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br. J. Haematol. 146(1), 120–122 (2009).
  Medline CASGoogle Scholar
• 45 Boztug H, Hirschmugl T, Holter W et al. NF-kappaB1 haploinsufficiency causing immunodeficiency and EBV-driven lymphoproliferation. J. Clin. Immunol. 36(6), 533–540 (2016).
  Medline CASGoogle Scholar
• 46 Van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. 72(9), 1496–1502 (2013). •• Descriptive analysis of hypogammaglobulinemia in rheumotoid arthritis patients treated with rituximab.
  Medline CASGoogle Scholar
• 47 Makatsori M, Kiani-Alikhan S, Manson AL et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM 107(10), 821–828 (2014).
  Medline CASGoogle Scholar
• 48 Nishio M, Fujimoto K, Yamamoto S et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur. J. Haematol. 77(3), 226–232 (2006). •• Descriptive study on impaired isotype switching and B cell reconstitution in Rituximab-treated patients post autologous stem cell transplant.
  Medline CASGoogle Scholar
• 49 Witzens-Harig M, Foa R, Di Rocco A et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the Phase IIIb MAXIMA study. Ann. Hematol. 93(10), 1717–1724 (2014).
  Medline CASGoogle Scholar
• 50 Product Information: RITUXAN(R) intravenous injection, rituximab intravenous injection. (2016).
  Google Scholar
• 51 Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G. Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins. Arthritis Care Res. (Hoboken) 69(6), 857–866 (2017).
  Medline CASGoogle Scholar
• 52 Roberts DM, Jones RB, Smith RM et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J. Autoimmun. 57, 60–65 (2015).
  Medline CASGoogle Scholar
• 53 Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 53(10), 1818–1824 (2014).
  Medline CASGoogle Scholar
• 54 Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G. Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins. Arthritis Care Res. (Hoboken) 69(6), 857–866 (2017).
  Medline CASGoogle Scholar
• 55 Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103(12), 4416–4423 (2004).
  Medline CASGoogle Scholar
• 56 Kano G, Nakatani T, Yagi K, Sakamoto I, Imamura T. Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia. Immunol. Lett. 159(1–2), 76–78 (2014). • Case report outlining distrupted kinetics of memory B-cell development following rituximab treatment.
  Medline CASGoogle Scholar
• 57 Delbe-Bertin L, Aoun B, Tudorache E, Lapillone H, Ulinski T. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr. Nephrol. 28(3), 447–451 (2013).
  MedlineGoogle Scholar
• 58 Besada E. Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab. BMC Musculoskelet. Disord. 17, 6 (2016).
  MedlineGoogle Scholar
• 59 Irie E, Shirota Y, Suzuki C et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int. J. Hematol. 91(3), 501–508 (2010).
  Medline CASGoogle Scholar
• 60 Filanovsky K, Miller EB, Sigler E, Berrebi A, Shvidel L. Incidence of profound hypogammaglobulinemia and infection rate in lymphoma patients following the combination of chemotherapy and rituximab. Recent Pat. Anticancer Drug Discov. 11(2), 228–235 (2016).
  Medline CASGoogle Scholar
• 61 Hicks LK, Woods A, Buckstein R et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant. 43(9), 701–708 (2009).
  Medline CASGoogle Scholar
• 62 Walker AR, Kleiner A, Rich L et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest. 26(4), 431–433 (2008).
  MedlineGoogle Scholar
• 63 Nishio M, Endo T, Fujimoto K et al. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur. J. Haematol. 82(2), 143–147 (2009). • Study showing low IgG and IgA levels in FCGR3A-158F homozygous patients receiving autologous stem cell transplant with adjuvant rituximab for non-Hodgkin's lymphoma.
  Medline CASGoogle Scholar
• 64 Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3), 754–758 (2002).
  Medline CASGoogle Scholar
• 65 Hatjiharissi E, Xu L, Santos DD et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110(7), 2561–2564 (2007).
  Medline CASGoogle Scholar
• 66 Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103(10), 3684–3688 (2004).
  Medline CASGoogle Scholar
• 67 Bredemeier M, De Oliveira FK, Rocha CM. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 66(2), 228–235 (2014).
  Medline CASGoogle Scholar
• 68 Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6(6), 326–337 (2010).
  Medline CASGoogle Scholar
• 69 Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66(5), 700–703 (2007).
  Medline CASGoogle Scholar
• 70 Kraaij T, Kamerling SWA, De Rooij ENM et al. Synergetic B-cell immunomodulation with rituximab and belimumab combination treatment in severe, refractory SLE. Arthritis Rheumatol. 69(Suppl. 10), Abstract 890 (2017).
  Google Scholar
• 71 Thiel J, Rizzi M, Engesser M et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res. Ther. 19(1), 101 (2017).
  MedlineGoogle Scholar
• 72 Dass S, Rawstron AC, Vital EM, Henshaw K, Mcgonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58(10), 2993–2999 (2008).
  Medline CASGoogle Scholar
• 73 Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis – emerging patterns and paradigms. Arthritis Rheum. 54(8), 2356–2367 (2006).
  Medline CASGoogle Scholar
• 74 St Clair EW. Good and bad memories following rituximab therapy. Arthritis Rheum. 62(1), 1–5 (2010).
  Medline CASGoogle Scholar
• 75 Kamburova EG, Koenen HJ, Borgman KJ, Ten Berge IJ, Joosten I, Hilbrands LB. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am. J. Transplant. 13(6), 1503–1511 (2013).
  Medline CASGoogle Scholar
• 76 Mahevas M, Patin P, Huetz F et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J. Clin. Invest. 123(1), 432–442 (2013).
  Medline CASGoogle Scholar
• 77 Audia S, Samson M, Guy J et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 118(16), 4394–4400 (2011).
  Medline CASGoogle Scholar
• 78 Pers JO, Daridon C, Bendaoud B et al. B-cell depletion and repopulation in autoimmune diseases. Clin. Rev. Allergy Immunol. 34(1), 50–55 (2008).
  Medline CASGoogle Scholar
• 79 Sutter JA, Kwan-Morley J, Dunham J et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin. Immunol. 126(3), 282–290 (2008).
  Medline CASGoogle Scholar
• 80 Kessel A, Rosner I, Toubi E. Rituximab: beyond simple B cell depletion. Clin. Rev. Allergy Immunol. 34(1), 74–79 (2008).
  Medline CASGoogle Scholar
• 81 Anolik JH, Friedberg JW, Zheng B et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin. Immunol. 122(2), 139–145 (2007).
  Medline CASGoogle Scholar
• 82 Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab–for how long? J. Allergy Clin. Immunol. 136(5), 1407–1409 (2015).
  MedlineGoogle Scholar
• 83 Masjosthusmann K, Ehlert K, Eing BR et al. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. Bone Marrow Transplant. 43(9), 679–684 (2009).
  Medline CASGoogle Scholar
• 84 Piro LD, White CA, Grillo-Lopez AJ et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10(6), 655–661 (1999).
  Medline CASGoogle Scholar
• 85 Ghielmini M, Rufibach K, Salles G et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 16(10), 1675–1682 (2005).
  Medline CASGoogle Scholar
• 86 Md Yusof MY, Vital EM, Das S et al. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. Ann. Rheum. Dis. 74(9), 1734–1738 (2015).
  MedlineGoogle Scholar
• 87 Bingham CO 3rd, Looney RJ, Deodhar A et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 62(1), 64–74 (2010).
  Medline CASGoogle Scholar
• 88 Mauri C, Menon M. The expanding family of regulatory B cells. Int. Immunol. 27(10), 479–486 (2015).
  Medline CASGoogle Scholar
• 89 Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity 42(4), 607–612 (2015).
  Medline CASGoogle Scholar
• 90 Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58(6), 1566–1575 (2008).
  Medline CASGoogle Scholar
• 91 Dunleavy K, Hakim F, Kim HK et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106(3), 795–802 (2005).
  Medline CASGoogle Scholar
• 92 Li J, Levi M, Charoin JE et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in Non-Hodgkin's lymphoma (NHL) patients. Blood 110(11), 700a–700a (2007).
  Google Scholar
• 93 Mogensen TH, Bernth-Jensen JM, Petersen CC et al. Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with rituximab. BMC Hematol. 13(1), 4 (2013).
  MedlineGoogle Scholar
• 94 Chase NM, Verbsky JW, Hintermeyer MK et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J. Clin. Immunol. 33(1), 30–39 (2013).
  Medline CASGoogle Scholar
• 95 Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun. Rev. 6(4), 257–259 (2007).
  Medline CASGoogle Scholar
• 96 Palabrica FR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac. Allergy 3(4), 249–256 (2013).
  MedlineGoogle Scholar
• 97 Windegger TM, Lambooy CA, Hollis L, Morwood K, Weston H, Fung YL. Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy. Transfus. Med. Rev. 31(1), 45–50 (2017).
  MedlineGoogle Scholar
• 98 Yong PF, Thaventhiran JE, Grimbacher B. ‘A rose is a rose is a rose’, but CVID is not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv. Immunol. 111, 47–107 (2011).
  Medline CASGoogle Scholar
• 99 Bonilla FA, Khan DA, Ballas ZK et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J. Allergy Clin. Immun. 136(5), 1186–1205.e1-e78 (2015).
  MedlineGoogle Scholar
• 100 Stiehm ER, Ochs HA, Winklestein JA, Rich E. Immunologic Disorders in Infants and Children (5th Edition). Saunders, PA, USA, 1512 (2004).
  Google Scholar
• 101 Buckley RH. Immunoglobulin G subclass deficiency: fact or fancy? Curr. Allergy Asthma Rep. 2(5), 356–360 (2002).
  MedlineGoogle Scholar
• 102 Roberts DM, Jones RB, Smith RM et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J. Autoimmun. 57, 24–29 (2015).
  Medline CASGoogle Scholar
• 103 Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS ONE 9(6), e100324 (2014).
  MedlineGoogle Scholar
• 104 Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica 99(6), 1101–1106 (2014).
  Medline CASGoogle Scholar
• 105 Kado R, Sanders G, Mccune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy. Curr. Opin. Rheumatol. 29(3), 228–233 (2017).
  Medline CASGoogle Scholar
• 106 Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann. NY Acad. Sci. 1173, 683–691 (2009).
  Medline CASGoogle Scholar